AbbVie's hepatitis C Phase III trials all record top results

US drugmaker AbbVie (NYSE: ABBV) has announced the completion of its Phase III clinical program and released results of four additional studies designed to assess its investigational all-oral, interferon-free therapy with and without ribavirin (RBV) in patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.

The results demonstrate high sustained virologic response rates 12 weeks post treatment (SVR12) and tolerability in these GT1 patients. All of the six trials showed a SVR12 rate of between 90-100%.

Scott Brun, vice president, pharmaceutical development at AbbVie, said: “The outcomes of AbbVie’s comprehensive Phase III studies in 2,300 patients across 25 countries demonstrate how our investigational regimen performs across a broad spectrum of genotype 1 patients, including those with compensated liver cirrhosis. The high rates of response and tolerability of our regimen, coupled with the low rates of discontinuation are promising.”